International Myeloma Society Educational Workshop 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: hematologists, medical oncologists, nephrologists, and infectious disease specialists

+ Sample video: contact me for sample video

+ Information:

This dynamic educational workshop focuses on the diagnosis, treatment, and monitoring of plasma cell malignancies, exploring both current practices and opportunities for improvement. The program features a blend of lectures and interactive roundtable discussions centered on hot and controversial topics. It highlights point-counterpoint conversations between invited speakers and local hematologists, utilizing challenging clinical cases and questions to drive the educational experience in the evolving landscape of multiple myeloma.

Learning Objectives

Upon completion of this workshop, participants will be able to:

• Evaluate current diagnostic testing, minimal residual disease (MRD) testing, and new risk stratification models for multiple myeloma.

• Determine optimal management strategies for Smoldering Multiple Myeloma (SMM) and Newly Diagnosed Multiple Myeloma (NDMM), differentiating between transplant-eligible and non-eligible patients.

• Design effective sequencing strategies for relapsed and refractory multiple myeloma (RRMM) and incorporate novel immunotherapies, including CAR T cells and bispecific T cell engagers.

• Manage myeloma-related complications effectively, particularly bone disease, renal failure, and treatment-related infections.

• Formulate treatment plans for challenging clinical scenarios, such as extramedullary disease, plasma cell leukemia, patient frailty, and relapse after T cell-redirected therapies.

• Address and manage other plasma cell disorders, specifically Waldenström’s Macroglobulinemia and AL Amyloidosis.

Target Audience

• The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
• Best for hematologists, medical oncologists, nephrologists, and infectious disease specialists.

Topics

• Multiple Myeloma: A Cure is on the Horizon

• Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up

• Update and Recommendations on Imaging Techniques in Myeloma

• MRD Testing in Multiple Myeloma

• New Risk Stratification in Multiple Myeloma

• Live Panel Discussion: Diagnosis and Follow Up of Patients

• Management of Clinical Significance/Smoldering Myeloma

• Management of Newly Diagnosed MM Transplant Eligible

• Management of Newly Diagnosed MM Non-Transplant Eligible

• Live Panel Discussion: How to Manage SMM and NDMM

• The Future of Multiple Myeloma

• Optimal Sequencing for RRMM Patients in Their 1st and 2nd Relapse

• Novel Treatments for MM Besides Cell Therapies and Bispecifics

• Live Panel Discussion: Sequencing of Therapies in RRMM

• CAR T Cells

• Bispecific T Cell Engagers

• Live Panel Discussion: Incorporating Novel Immunotherapies in Practice

• Bone Disease and Renal Failure

• Infection and Vaccinations

• Live Panel Discussion: Managing Myeloma Related Complications

• Waldenström’s Macroglobulinemia

• AL Amyloidosis

• Live Panel Discussion: Managing Other Dysproteinemias

• Relapse After T Cell Redirected Therapies

• Extramedullary Disease and Plasma Cell Leukemia

• Incorporating Frailty Into Treatment Algorithms for MM

• Live Panel Discussion: Challenging Questions in MM